Markedly enhanced levodopa pharmacokinetics from continuous subcutaneous carbidopa administration

被引：0

作者：

Yacoby-Zeevi, O. ^{[1
]}

Oren, S. ^{[1
]}

LeWitt, P. ^{[2
,3
]}

机构：

[1] NeuroDerm Ltd, Ness Ziona, Israel

[2] Wayne State Univ, Sch Med, Southfield, MI USA

[3] Henry Ford Hosp, Southfield, MI USA

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2010年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：52 / 52

页数：1

共 50 条

[31] Continuous subcutaneous levodopa/ carbidopa infusion for Parkinson's disease: 3-year data from the BeyoND study
Poewe, W.
Stocchi, F.
Adar, L.
Sopromadze, S.
Yardeni, T.
Giladi, N.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 313 - 313
[32] EFFECT OF ENTACAPONE, A COMT INHIBITOR, ON THE PHARMACOKINETICS AND METABOLISM OF LEVODOPA AFTER ADMINISTRATION OF CONTROLLED-RELEASE LEVODOPA-CARBIDOPA IN VOLUNTEERS
AHTILA, S
KAAKKOLA, S
GORDIN, A
KORPELA, K
HEINAVAARA, S
KARLSSON, M
WIKBERG, T
TUOMAINEN, P
MANNISTO, PT
CLINICAL NEUROPHARMACOLOGY, 1995, 18 (01) : 46 - 57
[33] Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson's disease: is it an improvement on other delivery?
Doggrell, Sheila A.
EXPERT OPINION ON DRUG DELIVERY, 2023, 20 (09) : 1189 - 1199
[34] Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
Ahmed A. Othman
Krai Chatamra
Mohamed-Eslam F. Mohamed
Sandeep Dutta
Janet Benesh
Masayoshi Yanagawa
Masahiro Nagai
Clinical Pharmacokinetics, 2015, 54 : 975 - 984
[35] Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration
Jost, Wolfgang H.
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (04) : 447 - 458
[36] Constant therapeutic levodopa (LD) plasma concentrations maintained by continuous subcutaneous (SC) administration of ND-0612, a novel formulation of LD/carbidopa (CD)
Caraco, Y.
Oren, S.
LeWitt, P.
MOVEMENT DISORDERS, 2013, 28 : S162 - S162
[37] Lack of Notable Skin Reactions from a Novel Levodopa/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site
Facheris, M.
Qi, X.
Locke, C.
Rosebraugh, M.
Benesh, J.
MOVEMENT DISORDERS, 2019, 34 : S39 - S39
[38] THE EFFECT OF CARBIDOPA ON AGE-RELATED CHANGES IN THE PHARMACOKINETICS OF LEVODOPA
ROBERTSON, DRC
WOOD, N
EVEREST, H
WALLER, DG
RENWICK, AG
GEORGE, CF
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (01) : P106 - P106
[39] THE EFFECT OF AGE ON THE PHARMACOKINETICS OF LEVODOPA ADMINISTERED ALONE AND IN THE PRESENCE OF CARBIDOPA
ROBERTSON, DRC
WOOD, ND
EVEREST, H
MONKS, K
WALLER, DG
RENWICK, AG
GEORGE, CF
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (01) : 61 - 69
[40] Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease
Mueller, Thomas
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (05) : 403 - 414

← 1 2 3 4 5 →